Prognostic Model in Renal Cell Carcinoma After Nephrectomy
A prognostic model adjusting for clinical variables and incorporating the multigene cell-cycle proliferation score may prove to be an accurate way to predict long-term outcomes in patients with renal cell carcinoma. The details regarding this prognostic model, which was derived from molecular tissue analysis and clinical evaluation of more than 500 patients with localized disease from the University of Michigan and Massachusetts General Hospital, were presented in a poster by developers Todd M. Morgan, MD, of the University of Michigan Comprehensive Cancer Center, Ann Arbor, and colleagues, at the 2017 National Comprehensive Cancer Network Annual Conference (Poster 46).
A total of 565 patients with clear cell, papillary, or chromophobe renal cell carcinoma were included in this study. The RNA-based CCP score (based on genes related to proliferation) was derived after radical nephrectomy. None of these patients had nodal or distant metastases.
“We adjusted for standard clinical variables and found the cell-cycle proliferation score was an independent prognosticator of outcomes,” stated Dr. Morgan in an interview with The ASCO Post.
The investigators found that patients who met low-risk criteria had a 99% disease-specific survival at 5 years, compared with 84% for patients in the high-risk group (P<.001). “There was a big spread according to risk. This suggests that by combining these factors, we can more accurately predict outcomes,” commented Dr. Morgan.